Tweet
Lupus Sci Med
. 2024 Sep 30;11(2):e001104.
doi: 10.1136/lupus-2023-001104. SARS-CoV-2 spike aggravates lupus nephritis and lung fibrosis in systemic lupus erythematosus
Yeon Su Lee 1 2 3 , Jin Seok Woo 1 , JooYeon Jhun 1 2 3 , Jeong Won Choi 1 2 , A Ram Lee 1 2 3 , Kun Hee Lee 1 2 3 , Haeyoun Choi 4 5 , Sung-Hwan Park 6 , Mi-La Cho 7 2 3
Affiliations
Objective: COVID-19 induces the development of autoimmune diseases, including SLE, which are characterised by inflammation, autoantibodies and thrombosis. However, the effects of COVID-19 on SLE remain unclear.
Methods: We investigated the effects of COVID-19 on SLE development and progression in three animal models. Plasmids encoding SARS-CoV-2 spike protein and ACE2 receptor were injected into R848-induced BALB/C lupus mice, R848-induced IL-1 receptor antagonist knockout (KO) lupus mice and MRL/lpr mice. Serum levels of albumin and autoantibodies, lymphocyte phenotypes and tissue histology were evaluated.
Results: In R848-induced BALB/C lupus mice, the SARS-CoV-2 spike protein increased autoantibody and albumin levels compared with vehicle and mock treatments. These mice also exhibited splenomegaly, which was further exacerbated by the spike protein. Flow cytometric analysis revealed elevated T helper 1 cell counts, and histological analysis indicated increased levels of the fibrosis marker protein α-smooth muscle actin. In KO mice, the spike protein induced splenomegaly, severe kidney damage and pronounced lung fibrosis. In the MRL/lpr group, spike protein increased the serum levels of autoantibodies, albumin and the thrombosis marker chemokine (C-X-C motif) ligand 4.
Conclusion: COVID-19 accelerated the development and progression of lupus by inducing autoantibody production, fibrosis and thrombosis.
Keywords: COVID-19; lupus erythematosus, systemic; lupus nephritis; pulmonary fibrosis.
. 2024 Sep 30;11(2):e001104.
doi: 10.1136/lupus-2023-001104. SARS-CoV-2 spike aggravates lupus nephritis and lung fibrosis in systemic lupus erythematosus
Yeon Su Lee 1 2 3 , Jin Seok Woo 1 , JooYeon Jhun 1 2 3 , Jeong Won Choi 1 2 , A Ram Lee 1 2 3 , Kun Hee Lee 1 2 3 , Haeyoun Choi 4 5 , Sung-Hwan Park 6 , Mi-La Cho 7 2 3
Affiliations
- PMID: 39349051
- DOI: 10.1136/lupus-2023-001104
Objective: COVID-19 induces the development of autoimmune diseases, including SLE, which are characterised by inflammation, autoantibodies and thrombosis. However, the effects of COVID-19 on SLE remain unclear.
Methods: We investigated the effects of COVID-19 on SLE development and progression in three animal models. Plasmids encoding SARS-CoV-2 spike protein and ACE2 receptor were injected into R848-induced BALB/C lupus mice, R848-induced IL-1 receptor antagonist knockout (KO) lupus mice and MRL/lpr mice. Serum levels of albumin and autoantibodies, lymphocyte phenotypes and tissue histology were evaluated.
Results: In R848-induced BALB/C lupus mice, the SARS-CoV-2 spike protein increased autoantibody and albumin levels compared with vehicle and mock treatments. These mice also exhibited splenomegaly, which was further exacerbated by the spike protein. Flow cytometric analysis revealed elevated T helper 1 cell counts, and histological analysis indicated increased levels of the fibrosis marker protein α-smooth muscle actin. In KO mice, the spike protein induced splenomegaly, severe kidney damage and pronounced lung fibrosis. In the MRL/lpr group, spike protein increased the serum levels of autoantibodies, albumin and the thrombosis marker chemokine (C-X-C motif) ligand 4.
Conclusion: COVID-19 accelerated the development and progression of lupus by inducing autoantibody production, fibrosis and thrombosis.
Keywords: COVID-19; lupus erythematosus, systemic; lupus nephritis; pulmonary fibrosis.